DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Biroccio A, Porru M, Rizzo A, Salvati E, D'Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi G, Pisano C, Zunino F, Leonetti C.
Biroccio A, et al. Among authors: zupi g.
Clin Cancer Res. 2011 Apr 15;17(8):2227-36. doi: 10.1158/1078-0432.CCR-10-3033. Epub 2011 Feb 25.
Clin Cancer Res. 2011.
PMID: 21355072